Tat analog (CPP) + AT1002 analog (TJ modulator)
Sequence: GRKKRRQRRRCG ; FCIGRLCG
| Experiment Id | EXP001398 |
|---|---|
| Paper | Therapeutic Effects on Atopic Dermatitis by Anti-RelA Short Interfering RNA Combined with Functional |
| Peptide | Tat analog (CPP) + AT1002 analog (TJ modulator) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | AT1002 400 µg per application; Tat amount corresponding to N/P=10 (mass not explicitly stated in treatment section) |
| Rna Concentration | siRelA 5 µg in 20 µL PBS per application; applied on days 11, 13, 15, 18, 20, 22 |
| Mixing Ratio | Tat/siRelA N/P=10; AT1002 co-applied |
| Formulation Format | Topical transdermal Tat/siRNA complex with AT1002 enhancer |
| Formulation Components | Tat analog + AT1002 analog + siRelA (anti-RelA siRNA) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | NC/Nga mouse atopic dermatitis model (picryl chloride-induced ear lesions) |
| Administration Route | Topical (ear skin application; transdermal) |
| Output Type | Therapeutic efficacy in vivo (ear thickness, dermatitis clinical score, ear cytokines TNF-α/IL-4, serum IgE) |
| Output Value | |
| Output Units | |
| Output Notes | Topical anti-RelA siRNA with Tat+AT1002 improved AD outcomes vs untreated controls, including reduced ear swelling, reduced clinical severity, decreased local cytokines, and decreased serum IgE. |
| Toxicity Notes | No treatment-limiting toxicity reported. |
| Curation Notes |